ICAAC Presentation: Immunization of Pregnant Baboons With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ICAAC Presentation: Immunization of Pregnant Baboons With the RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged With Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed With Palivizumab
  • Immunization of pregnant baboons generates anti-F IgG antibodies that are transferred from mothers to their infants
  • When challenged with RSV, infant baboons born to immunized mothers show equivalent protection to infant baboons receiving palivizumab (Synagis ®) therapy

GAITHERSBURG, Md., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX ) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants , today announced pre-clinical data presented on Sunday, September 7, 2014, at 54 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. These data demonstrate that immunization of pregnant baboons in the third trimester of pregnancy generates anti-F IgG antibodies that are transferred to the newborn infants. The study further demonstrated that infants born to immunized mothers were protected from RSV challenge at a level comparable to palivizumab (Synagis ®) therapy.

The ICAAC slide presentation 077: I-649, titled, "Immunization of Pregnant Baboons with the RSV F Nanoparticle Vaccine Protects Infant Baboons Challenged with Respiratory Syncytial Virus in a Comparable Manner to Infants Prophylaxed with Palivizumab" was presented by Dr. Robert Welliver of the University of Oklahoma, Health Sciences on Sunday, September 7.

Infant olive baboons develop RSV disease that mimics the clinical and pathological findings observed in human infants with RSV infection, making them an appropriate model for evaluation of maternal immunization with an RSV vaccine. Novavax, which is developing its RSV F-protein nanoparticle vaccine (RSV F nanoparticle vaccine) for maternal, pediatric and elderly immunizations to prevent RSV disease, collaborated with the University of Oklahoma on this study to evaluate the efficiency of maternal RSV F antibody transfer and the efficacy of its RSV vaccine in infants of vaccinated mother baboons compared to palivizumab recipients and untreated controls.

In this study, seronegative pregnant baboons (5 pairs) received either three intramuscular injections (IM) in the third trimester with a 60 μg/dose of the RSV vaccine and 1.2 mg of aluminum phosphate as an adjuvant at three week intervals, or saline. The paired infant baboons were challenged on day 30 intratracheally with 2-5x10 8 pfu 1 of respiratory syncytial virus (RSV). Similarly, 4 pairs of infant baboons were administered either 15mg/kg palivizumab or saline IM before the RSV challenge. Blood was collected on day 0 and bronchoalveolar lavage (BALs) was performed to assess lung viral load and leukocyte levels on day 0, 5, 7 and 10. Blinded observations of respiratory rates were made in pairs. Pulmonary function tests were performed in the infants of vaccinated and control mothers.

In recipients of the RSV F nanoparticle vaccine, antibody responses were measured in the mother on the day of birth (day 0 (zero)) and in the infant on day 30. Geometric mean anti-F IgG antibody titers were 115,535 Elisa Units (EU) and 32,774 EU, palivizumab competing antibodies (PCA) were 342 and 98 μg/ml and RSV A neutralizing antibodies (A MN) were 380 and 121, in the mothers and infants, respectively. Sera from infants administered palivizumab on day 29 had day 30 geometric mean anti-F IgG were 88,475 EU, PCA 196μg/ml and A MN 269. Palivizumab treated and infants of vaccinated mothers had significantly lower fold rise in respiratory rates compared to their matched, untreated pairs, (p=0.0008, and p=0.0028). Decreases in lung viral loads and BAL leukocytes were observed in treated infants. Reduced work of breathing and higher peak expiratory flow was observed in infants of vaccinated mothers.

"This study provides direct empirical evidence, in a relevant higher-primate model, to support the maternal immunization strategy for our RSV F nanoparticle vaccine," said Greg Glenn, M.D., Senior Vice President, Research and Development at Novavax. "While we were confident that we would see maternal transfer of anti-F antibodies, we now have evidence to show that our vaccine candidate can not only protect against RSV disease, but provide protection similar to palivizumab, and may provide superior anti-inflammatory benefits relative to palivizumab. This study adds to substantial evidence and validation supporting our RSV maternal immunization strategy as we move towards the initiation of our first study in pregnant women in the next few months."

About Novavax

Novavax, Inc. (Nasdaq: NVAX ) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

About RSV

RSV is a major respiratory pathogen in infants, children, and adults. RSV infections in adults represent re-infections and are generally mild to moderate in severity, except in persons with high-risk conditions including the elderly and adults with underlying chronic cardiac or pulmonary disease. It is estimated that between 11-17,000 adults die of RSV infection annually in the U.S., with and up to 180,000 admitted to hospital with respiratory symptoms. Currently, there is no approved RSV prophylactic vaccine available. Palivizumab is a monoclonal antibody, licensed and sold by Medimmune as Synagis®, that targets the RSV F protein and is used for prophylaxis against RSV disease in high risk infants.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2013, and filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read company filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the company undertakes no obligation to update or revise any of the statements. The company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

1 "Plaque Forming Units": PFU is a measurement of only those viral particles that will effectively produce a plaque and infect cells."
 

Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 15

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 45

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 67

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 43

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 132

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 228

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 69

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 74

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 34

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading

Top 5 Most Recently Viewed Articles

BARROT Showcases Groundbreaking Bluetooth Innovations at CES

Updated Category News Views 361

BARROT Introduces Innovative Bluetooth Technologies at CES 2025 At CES 2025, held in Las Vegas, BARROT, a prominent name in short-range wireless communication, proudly showcased its latest advancements in Bluetooth technology. The highlight of BARROT's presentation is its Bluetooth v6.0-qualified stack, which integrates various cutting-edge wireless solutions including...

Continue Reading
Explore Summer Adventures Awaiting in Myrtle Beach's Shores

Updated Category News Views 264

Experience Unforgettable Summer Days in Myrtle Beach There's still plenty of time to enjoy a sun-soaked getaway the whole family will love. The sun is shining, the days are stretching on, and there remains an abundance of summer left to indulge in cherished family adventures along the beautiful coastline of Myrtle Beach. Whether you're meticulously planning your escape or...

Continue Reading
NextNRG Surges Ahead with Impressive Growth Metrics and Strategy

Updated Category News Views 194

NextNRG Achieves Extraordinary Revenue Growth AI-Driven Energy Pioneer Delivers Sixth Consecutive Record Month Company on Clear Path to $100 Million Revenue Run-Rate with Canadian Acquisition NextNRG, Inc. (Nasdaq: NXXT) is shaping the future of energy with its innovative AI-driven solutions. Recently, the company announced outstanding preliminary financial results that...

Continue Reading
Insights on IES Hldgs's Increasing Short Interest

Updated Category News Views 137

Understanding IES Hldgs's Current Short Interest Trends IES Hldgs has recently experienced a notable increase in its short interest, with the short percent of float rising by 11.11% since the last update. Investors should be aware that the latest figures indicate 673 thousand shares sold short, accounting for 7.6% of all regular trading shares. Given its current trading...

Continue Reading
ALINA Residences Celebrates Luxury VERIFIED™ Status Award

Updated Category News Views 345

ALINA Residences: A New Victory in Luxury Living ALINA Residences, located in the heart of Boca Raton, recently snagged the spotlight with its shiny new VERIFIED™ Luxury Residences plaque from Forbes Travel Guide. To most, it might just seem like a piece of metal, but in the world of upscale living, this is a badge of honor. Celebrating Commitment to Service Excellence...

Continue Reading